177 related articles for article (PubMed ID: 35893702)
1. Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic.
Tai CM; Huang CK; Changchien TC; Lin PC; Wang DW; Chang TT; Chan HW; Chen TH; Tseng CH; Chen CC; Tsai CT; Sie YT; Yen YC; Yu ML
Viruses; 2022 Jul; 14(8):. PubMed ID: 35893702
[TBL] [Abstract][Full Text] [Related]
2. Collaborative Referral Model for Hepatitis C Screening and Treatment in a Remote Mountainous Region of Taiwan during the COVID-19 Pandemic.
Tai CM; Bair MJ; Chen TH; Tseng CH; Chen CC; Lam H; Yu ML
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112808
[TBL] [Abstract][Full Text] [Related]
3. Integrated care for methadone maintenance patients with hepatitis C virus infection.
Tai CM; Yen YC; Bair MJ; Tseng CH; Chang TT; Huang CF; Yeh ML; Dai CY; Chuang WL; Yu ML; Huang JF
Kaohsiung J Med Sci; 2019 Aug; 35(8):501-507. PubMed ID: 31087764
[TBL] [Abstract][Full Text] [Related]
4. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
7. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
8. Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan - A multi-center collaborative care model.
Lo CC; Lei WY; Huang YC; Hwang JJ; Lo CY; Lin CH; Cheng HS; Liao YT; Liang PC; Chiou MJ; Bair MJ; Dai CY; Yu ML
J Microbiol Immunol Infect; 2023 Aug; 56(4):680-687. PubMed ID: 36822945
[TBL] [Abstract][Full Text] [Related]
9. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada.
Selfridge M; Barnett T; Lundgren K; Guarasci K; Milne R; Drost A; Fraser C
Public Health Nurs; 2022 Sep; 39(5):1009-1016. PubMed ID: 35537120
[TBL] [Abstract][Full Text] [Related]
10. Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy.
Cooper MP; Foley H; Damico D; Wright M; Rhudy C; Schadler A; Platt T
J Manag Care Spec Pharm; 2022 Jun; 28(6):667-672. PubMed ID: 35621721
[No Abstract] [Full Text] [Related]
11. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study.
Liu Y; Zou X; Chen W; Gong C; Ling L
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31726750
[TBL] [Abstract][Full Text] [Related]
13. Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance.
Martinez AD; Dimova R; Marks KM; Beeder AB; Zeremski M; Kreek MJ; Talal AH
J Viral Hepat; 2012 Jan; 19(1):47-54. PubMed ID: 21129131
[TBL] [Abstract][Full Text] [Related]
14. A new collaborative care approach toward hepatitis C elimination in marginalized populations.
Su WW; Yang CC; Chang RW; Yeh YH; Yen HH; Yang CC; Lee YL; Liu CE; Liang SY; Sung ML; Ko SY; Kuo CY; Chen SL; Yeh YP; Hu TH;
J Infect Public Health; 2023 Aug; 16(8):1201-1208. PubMed ID: 37271101
[TBL] [Abstract][Full Text] [Related]
15. A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co-V2 pandemic.
Huang CI; Liang PC; Wei YJ; Tsai PC; Hsu PY; Hsieh MY; Liu TW; Lin YH; Hsieh MH; Jang TY; Wang CW; Yang JF; Yeh ML; Huang CF; Dai CY; Chuang WL; Huang JF; Yu ML
J Microbiol Immunol Infect; 2023 Jun; 56(3):586-597. PubMed ID: 37188573
[TBL] [Abstract][Full Text] [Related]
16. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
[TBL] [Abstract][Full Text] [Related]
17. Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.
McLeod A; Hutchinson SJ; Smith S; Leen C; Clifford S; McAuley A; Wallace LA; Barclay ST; Bramley P; Dillon JF; Fraser A; Gunson RN; Hayes PC; Kennedy N; Peters E; Templeton K; Goldberg DJ
HIV Med; 2021 May; 22(5):334-345. PubMed ID: 33350049
[TBL] [Abstract][Full Text] [Related]
18. HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
Hartl L; Jachs M; Bauer D; Simbrunner B; Chromy D; Binter T; Steininger L; Schwarz C; Schwarz M; Burghart L; Strassl R; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
J Viral Hepat; 2022 Dec; 29(12):1062-1072. PubMed ID: 36062398
[TBL] [Abstract][Full Text] [Related]
19. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).
Huang JF; Hsieh MY; Wei YJ; Hung JY; Huang HT; Huang CI; Yeh ML; Huang CF; Jang TY; Hsu PY; Liang PC; Dai CY; Lin ZY; Yu ML; Chuang WL
Hepatol Int; 2022 Feb; 16(1):59-67. PubMed ID: 34850326
[TBL] [Abstract][Full Text] [Related]
20. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
